RBC Capital Markets

Top 30 Global Ideas for 2023

Second-Quarter Update

EQUITY RESEARCH | April 3, 2023

For Required Non-U.S. Analyst and Conflicts Disclosures, see page 38

Disseminated: Apr 3, 2023 00:15EDT; Produced: Apr 3, 2023 00:08EDT

Table of Contents

This report is priced as of market close on March 31, 2023 unless otherwise noted.

Introduction

Graeme Pearson – Global Head of Research

Mark Odendahl – Head of US Research

André-Philippe Hardy – Head of Canadian & APAC Research

Michael Hall – Head of European Research & Global Head of Research Product Management

In this note, we present our *Top 30 Global Ideas* for Q2 2023. This list remains one of high-conviction, long-term ideas, with quarterly updates that enable dynamic changes into names that we think offer higher-conviction upside potential.

In Q1/23, the *Top 30* list delivered a total return of +11.9% in USD terms, above the MSCI World Index at +7.7%, with *Top 30* performance led by Meta Platforms (META US) at +76.1%, Palo Alto Networks (PANW US) at +43.1%, and R1 RCM (RCM US) at +37.0%. Since inception of our quarterly list at YE2019, the *Top 30* has delivered a total return of +37.8%, above the benchmark at +24.5%.

Globally, we share our US Equity Strategy team's view that 2023 will be a year of very modest gains as part of a messy post-crisis normalization similar to 2002-2003 and 2010-2011, with choppy conditions over the next few quarters amidst cuts to earnings forecasts, a bumpy moderation in inflation, and uncertainty regarding a transition in Fed policy and the onset of a challenging economy.

With the changes to the *Top 30* list this quarter, we switch into best ideas that we also view as offering more attractive positioning in the current environment. On an equal-weighted basis, we increase our Health Care weighting and decrease our Materials and Real Estate exposure, bringing our sector weightings more in line with the benchmark. We also increase our Financials exposure, now modestly Overweight vs. the benchmark, driven by the inclusion of individual high-conviction names and certain sub-sectors.

In **Financials**, we add leading financial markets infrastructure and data provider **London Stock Exchange Group (LSEG LN).** We expect operational momentum and the recently announced strategic partnership with Microsoft to drive a narrative shift and share price outperformance this year, with potential for a long-term positive re-rating to narrow the valuation gap between LSEG and its data provider peers. The recent orderly placement of ~£2B of shares by Refinitiv sellers should reduce the market's concerns regarding future placings, which could also serve as further buying opportunities, and fluctuations in interest rate expectations could provide a near-term revenue benefit for the group's capital markets venues.

In **Health Care**, we add biopharma company **Alnylam Pharmaceuticals (ALNY US)** and medical device company **Boston Scientific (BSX US)**, and remove **R1 RCM (RCM US)** while reiterating that it remains our top pick in our US HCIT coverage.

For Alnylam, we see key upcoming catalysts that we expect to unlock value near term and a pipeline that looks poised to deliver long term upside. We believe there is a high likelihood that the upcoming FDA Advisory Committee for drug candidate Onpattro will be positive, and expect FDA approval in October. ALNY is one of the few biopharma companies with a commercially validated platform, current revenue of ~$1B with visibility to >$3B if Onpattro for TTR-CM is successful, and M&A optionality.

Our addition of Boston Scientific reflects our view that the company is well positioned to beat and raise its initial 2023 organic sales growth guidance of 6-8% y/y as the year progresses, with a strong contribution from key franchises. In addition, we expect upcoming device launches and trial data readouts to serve as catalysts for BSX shares in 2023 and beyond.

In **Materials**, we remove **Nutrien (NTR US)** in favour of other ideas this quarter due to near-term headwinds for fertilizer prices and sentiment, while maintaining our Outperform rating. Although seasonally stronger North American spring fertilizer demand has started to emerge, we currently see limited price upside over the next few months before the typical summer slowdown. That said, Nutrien remains our preferred fertilizer stock and we continue to see a very constructive long-term fundamental outlook for ag and fertilizers supporting robust free cash flow generation for several years.

In **Real Estate**, within Communication Infrastructure, we remove **SBA Communications (SBAC US)** while maintaining our Outperform rating and our view of SBA as the clearest beneficiary of ongoing mobile 5G deployments.

This report contains further detail on our investment thesis for each *Top 30* name beginning on page 7. We encourage you to reach out to our team to continue the dialogue regarding their investment ideas.

We also highlight our flagship research products: RBC Fusion™, RBC Imagine™, RBC Elements™, and RBC ESG Stratify™. RBC Fusion offers peer-reviewed, unique reports on our highest-conviction, most-differentiated calls. RBC Imagine is a series of fundamental research focused on disruptive forces that we believe will transform the world. RBC Elements features proprietary insights generated with our internal data science team. RBC ESG Stratify separates the signal from the noise on ESG matters with precise, analytical research.

Top 30 Global Ideas for 2023 — Changes this Quarter

Additions: Alnylam Pharmaceuticals (ALNY US), Boston Scientific (BSX US), London Stock Exchange Group (LSEG LN)

Deletions: Nutrien (NTR US), R1 RCM (RCM US), SBA Communications (SBAC US)

Top 30 Global Ideas for 2023 — Pricing Data

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price (03/31/2023)	Market Cap (MM)	Price Target	Div. Yield (%)	Implied All-in Return (%)
Alimentation Couche-Tard Inc.	ATD CN	Irene Nattel	Outperform	CAD	68.00	67,345	85.00	0.8	25.8
Alnylam Pharmaceuticals, Inc.	ALNY US	Luca Issi	Outperform	USD	200.32	24,693	275.00	0.0	37.3
American International Group, Inc.	AIG US	Mark Dwelle	Outperform	USD	50.36	38,017	75.00	2.5	51.5
Anheuser-Busch InBev SA/NV	ABI BB	James Edwardes Jones	Outperform	EUR	61.33	123,457	72.00	1.6	19.0
Boston Scientific Corporation	BSX US	Shagun Singh	Outperform	USD	50.03	72,163	53.00	0.0	5.9
Canadian Natural Resources Limited	CNQ CN	Greg Pardy	Outperform	CAD	74.79	82,466	89.00	4.8	23.8
Canadian Pacific Railway Limited	CP CN	Walter Spracklin	Outperform	CAD	104.07	97,118	122.00	0.7	18.0
Constellation Software Inc.	CSU CN	Paul Treiber	Outperform	CAD	2,540.91	53,846	3,000.00	0.2	18.3
CrowdStrike Holdings, Inc.	CRWD US	Matthew Hedberg	Outperform	USD	137.26	33,931	160.00	0.0	16.6
CSL Limited	CSL AU	Craig Wong-Pan	Outperform	AUD	287.73	138,601	352.00	1.2	23.6
Diamondback Energy, Inc.	FANG US	Scott Hanold	Outperform	USD	135.17	24,816	182.00	8.7	43.4
DuPont de Nemours, Inc.	DD US	Arun Viswanathan	Outperform	USD	71.77	37,033	92.00	1.7	29.9
Element Fleet Management Corp.	EFN CN	Geoffrey Kwan	Outperform	CAD	17.75	6,967	27.00	2.3	54.4
Ferrari N V	RACE IM	Tom Narayan	Outperform	EUR	249.30	45,622	283.00	0.4	13.9
HEICO Corporation	HEI US	Ken Herbert	Outperform	USD	171.04	23,596	190.00	0.1	11.2
Inditex	ITX SM	Richard Chamberlain	Outperform	EUR	30.90	96,210	32.00	4.2	7.8
London Stock Exchange Group plc	LSEG LN	Ben Bathurst	Outperform	GBp	7,868.00	43,825	10,200.00	1.5	31.2
Lonza Group AG	LONN SW	Charles Weston	Outperform	CHF	547.40	40,764	760.00	0.6	39.5
M&T Bank Corporation	MTB US	Gerard Cassidy	Outperform	USD	119.57	20,207	183.00	4.0	57.1
Mastercard Incorporated	MA US	Daniel R. Perlin	Outperform	USD	363.41	349,964	392.00	0.5	8.4
Meta Platforms, Inc.	META US	Brad Erickson	Outperform	USD	211.94	559,522	225.00	0.0	6.2
Palo Alto Networks, Inc.	PANW US	Matthew Hedberg	Outperform	USD	199.74	74,263	216.00	0.0	8.1
PG&E Corporation	PCG US	Shelby Tucker	Outperform	USD	16.17	32,099	20.00	0.0	23.7
Restaurant Brands International Inc.	QSR US	Christopher Carril	Outperform	USD	67.14	31,831	81.00	2.7	23.3
S&P Global Inc.	SPGI US	Ashish Sabadra	Outperform	USD	344.77	112,119	434.00	1.0	26.9
Siemens Aktiengesellschaft	SIE GR	Mark Fielding	Outperform	EUR	149.34	121,861	160.00	2.4	9.5
TELUS Corporation	T CN	Drew McReynolds	Outperform	CAD	26.83	38,394	33.00	5.4	28.4
Veeva Systems Inc.	VEEV US	Rishi Jaluria	Outperform	USD	183.79	29,793	225.00	0.0	22.4
Ventas, Inc.	VTR US	Michael Carroll	Outperform	USD	43.35	17,496	56.00	4.2	33.3
WESCO International, Inc.	WCC US	Deane Dray	Outperform	USD	154.54	8,099	215.00	1.0	40.1

Note:

Past performance is not necessarily indicative of future performance. Price performance does not take into account relevant costs, including commissions and interest charges or other applicable expenses that may be associated with transactions in these shares.

Source: Bloomberg and RBC Capital Markets

Top 30 Global Ideas for 2023 — Changes This Quarter

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price (03/31/2023)	Market Cap (MM)	Price Target	Div. Yield (%)	Implied All-in Return (%)
Additions this quarter:									
Alnylam Pharmaceuticals, Inc.	ALNY US	Luca Issi	Outperform	USD	200.32	24,693	275.00	0.0	37.3
Boston Scientific Corporation	BSX US	Shagun Singh	Outperform	USD	50.03	72,163	53.00	0.0	5.9
London Stock Exchange Group plc	LSEG LN	Ben Bathurst	Outperform	GBp	7,868.00	43,825	10,200.00	1.5	31.2
Deletions this quarter:									
Nutrien Ltd.	NTR US	Andrew Wong	Outperform	USD	73.85	36,851	110.00	2.9	51.8
R1 RCM Inc.	RCM US	Sean Dodge	Outperform	USD	15.00	6,251	18.00	0.0	20.0
SBA Communications Corporation	SBAC US	Jonathan Atkin	Outperform	USD	261.07	28,534	320.00	1.3	23.9

Notes:

Past performance is not necessarily indicative of future performance. Price performance does not take into account relevant costs, including commissions and interest charges or other applicable expenses that may be associated with transactions in these shares.

Source: Bloomberg and RBC Capital Markets

Top 30 Global Ideas — Performance Summary

Although the *Top 30* is not intended to be a relative product, having been created to capture RBC Capital Markets' best ideas on an absolute basis, we compare the performance of the *Top 30* to the MSCI Developed World Index and regional indices to provide context for its returns. See the performance tables below for Q1 2023 and since inception (December 2019).

Ticker	Company	Total Return Q1/2023 (in local currency)	Total Return Q1/2023 (in USD)
META US	Meta Platforms, Inc.	76.1%	76.1%
PANW US	Palo Alto Networks, Inc.	43.1%	43.1%
RCM US	R1 RCM Inc.	37.0%	37.0%
CRWD US	Crowdstrike Holdings, Inc.	30.4%	30.4%
RACE IM	Ferrari NV	24.5%	26.4%
ITX SM	Inditex	24.3%	26.2%
WCC US	WESCO International, Inc.	23.7%	23.7%
CSU CN	Constellation Software Inc.	22.7%	22.8%
LONN SW	Lonza Group AG	20.8%	21.9%
SIE GR	Siemens AG	18.4%	20.1%
ATD CN	Alimentation Couche-Tard Inc.	14.5%	14.6%
VEEV US	Veeva Systems Inc.	13.9%	13.9%
HEI US	HEICO Corporation	11.4%	11.4%
ABI BB	Anheuser-Busch InBev SA/NV	9.0%	10.6%
DD US	DuPont de Nemours, Inc.	5.1%	5.1%
QSR US	Restaurant Brands International Inc.	4.7%	4.7%
MA US	Mastercard Incorporated	4.7%	4.7%
T CN	TELUS Corporation	4.0%	4.1%
SPGI US	S&P Global Inc.	3.2%	3.2%
CP CN	Canadian Pacific Railway Limited	3.2%	3.2%
NTR US	Nutrien Ltd.	1.9%	1.9%
FANG US	Diamondback Energy, Inc.	0.8%	0.8%
CNQ CN	Canadian Natural Resources Limited	0.8%	0.8%
CSL AU	CSL Limited	0.7%	-1.0%
PCG US	PG&E Corporation	-0.6%	-0.6%
VTR US	Ventas, Inc.	-2.8%	-2.8%
EFN CN	Element Fleet Management Corp.	-3.2%	-3.2%
SBAC US	SBA Communications Corporation	-6.5%	-6.5%
MTB US	M&T Bank Corporation	-16.9%	-16.9%
AIG US	American International Group, Inc.	-19.9%	-19.9%
	Average total return for RBC CM Top 30 Global Ideas in Q1 2023	*11.6%*	*11.9%*

Indices		Total Return (in local currency) Q1/2023	Total Return (in local currency) Since Inception (Not annualized)
	RBC CM Top 30 Global Ideas	11.6%	39.7%
SXXP Index	STOXX Europe 600 Index	8.6%	21.4%
NDDUWI Index	MSCI World Net Total Return US	7.7%	24.5%
SPX Index	S&P 500 Index	7.5%	34.1%
SPTSX Index	S&P/TSX Composite Index	4.6%	30.2%
AS51 Index	S&P/ASX 200 Index	4.0%	26.8%

Indices		Total Return (in USD) Q1/2023	Total Return (in USD) Since Inception (Not annualized)
	RBC CM Top 30 Global Ideas	11.9%	37.8%
SXXP Index	STOXX Europe 600 Index	10.2%	17.5%
NDDUWI Index	MSCI World Net Total Return US	7.7%	24.5%
SPX Index	S&P 500 Index	7.5%	34.1%
SPTSX Index	S&P/TSX Composite Index	4.6%	25.0%
AS51 Index	S&P/ASX 200 Index	2.2%	21.0%

Notes: Since inception performance calculated from YE2019. Past performance is not necessarily indicative of future performance. Price performance does not take into account relevant costs, including commissions and interest charges or other applicable expenses that may be associated with transactions in these shares.

Source: Bloomberg and RBC Capital Markets

Investment Thesis

Alimentation Couche-Tard Inc. (TSX: ATD)

RBC Dominion Securities Inc.
Irene Nattel (Analyst) (514) 878-7262, irene.nattel@rbccm.com

Rating: Outperform | **Closing Price: CAD 68.00**
Price Target: CAD 85.00 | **Implied All-in Return (%): 25.8**

Investment summary

Despite challenging macro backdrop, multiple avenues for growth, underpinned by: (1) top-line momentum from a more-focused, data-driven approach to merchandising/promotional strategies; (2) well-defined initiatives and strategies to optimize procurement; (3) focus on localized merchandise pricing, promotions, and assortments; (4) innovative fuel initiatives, including rollout of Circle-K gas; (5) cost optimization; (6) network development; and (7) opportunistic acquisitions.

On track to exceed F23 EBITDA objective of $5.1B excluding merger and acquisition. Solid underlying operating performance aided by focused execution of strategies outlined at mid-2021 investor event to deliver "double again" objective.

Industry performance in North America through COVID and during prior downturns reinforces defensive sector attributes. Despite high gas prices/opex increases, sustained elevated gas margins should enable ATD to offset gallon weakness related to dislocations.

Attractive geographic diversification with >85% of GP$ generated outside Canada.

Real-world EV R&D lab in Norway. ATD is the only North American c-store player with a strong footprint in Norway, the global leader in EV sales. With the operation of charging stations on its sites in addition to home and office chargers, ATD is gaining valuable insight into consumer behaviour/revenue opportunities.

Strong B/S + FCF profile with forecast FCF well in excess of $2B to fund activity on NCIB (F23 program up to 10% of float), dividend growth, debt repayment, and acquisitions. Adjusted net debt/EBITDAR sustained below 1.5x despite activity on NCIB, well below the post-SFR peak of 3.6x, with normalized estimated balance sheet capacity in excess of US$15B.

Valuation

Taking the midpoint of 19x TTM Q3/F25E (~C24E) EPS and 11.75x EBITDA drives our price target of $85, which supports our Outperform rating. The EBITDA multiple is consistent with the average of the five-year range, reflecting overall sector valuation trends, and supported by ongoing strong normalized underlying performance, relatively recession-resistant business model, and benefits from prior-period merger and acquisition. We believe the multiples are also appropriate relative to our c-store coverage universe based on relative investment attributes.

Risks to rating and price target

Normalization of gas margins without volume improvement would result in earnings below expectations. Substantial dislocation in inside store volumes could reduce inside-store contribution. Although c-stores typically are relatively recession-resistant, ~50% of US c-store customers have incomes ≤$60k and could be hard-hit by a recession as inflation reaches 40-year highs and interest rates rise. With ATD's diversified geographic footprint, the risk profile of forecasts includes multiple geographies and currencies, and economic and operating environments, each of which is being impacted at differing levels by current dislocation in Europe and surging energy prices. Potential merger and acquisition not included in our forecasts could result in earnings/share price that differs from forecasts.

Exhibit 1 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 2 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

RBC Capital Markets, LLC
Luca Issi, Ph.D. (Analyst) (212) 266-4089, luca.issi@rbccm.com

Rating: Outperform | **Closing Price: USD 200.32**
Price Target: USD 275.00 | **Implied All-in Return (%): 37.3**

Investment summary

We See Top-Line Likely To Inflect Soon – We think ALNY's top line ($1b today) is poised to triple by 2026. This is primarily driven by expansion into TTR-CM, a market where PFE's Vyndaqel generates ~$3b/year in revenue. First opportunity to access that market is upcoming as ALNY is facing an AdCom (likely in August) and an FDA decision by October 8th, 2023. Overall, while we do expect a heated debate at the AdCom given a relatively modest benefit in functional outcomes (6MWT), we think the drug ultimately gets approved as the 6MWT benefit can be substantiated by statistically significant benefit for patient reported outcomes (KCCQ), the majority of secondary endpoints including biomarkers (proBNP, troponin I), imaging (PYP scintigraphy/echocardiographic parameters) and early look at mortality all trending in the right direction. In the context of a drug that is safe and has been on the market for close to half a decade now, we believe approval is likely. Should that not be the case, ALNY has a second shot of goal as HELIOS-B reads out in early-24 and most of the docs we have spoken with believe the trial is likely to be successful.

Rich Calendar Ahead with Many Potential Catalysts – Beyond Onpattro's AdCom/approval, we see a rich calendar ahead with multiple catalysts with favorable skews that include Phase II for hypertension (we like clinical POC in hand and a market 300x bigger vs TTR-CM), Phase I for Alzheimer's/cerebral amyloid angiopathy (we think 50% KD is achievable and Alzheimer's will help attract generalist's interest), Phase II/Phase III data for HBV/Hemophilia (we like muted expectations), and Phase I for diabetes (we like a novel target/strong biologic rationale).

Commercially Validated Platform With Potential For Strategic Interest – We view ALNY as one of the few clinically and commercially validated platforms in Biotech given five approvals in less than four years and ~$1b top-line. M&A potential is a frequent topic of debate (especially given prior transactions in the space – DRNA, MDCO, Sirna) and prior press (*Bloomberg, Fierce Pharma - unconfirmed*) suggesting ALNY could be on NVS's short list of targets. While we think M&A is nice to have, we are making a fundamental call as we think the platform is poised to unlock further value for patients and shareholders and we see upside ahead of key catalysts.

Valuation

Our base case assumes 100% PoS for lumasiran, 85% for inclisiran, 90% for TTR, 45% for zilebesiran, 15% for Alzheimer's disease, 15% for T2D and 65% for fitusiran. Our $275 price target is based on a DCF that assumes a 10% WACC (same for all stocks in our coverage) and a 1% terminal growth rate (with a 0–2% range applied to our coverage depending on the relative maturity of the platforms). Our $275 price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) Onpattro fails to gain approval for TTR-CM; (2) current epidemiology for AHP and PH substantially underestimates opportunity; and (3) emergence of a safety signal in an ongoing clinical trial.

Exhibit 3 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 4 - Forward consensus EV/sales history



Source: Factset

Most recent company note: link

American International Group, Inc. (NYSE: AIG)

RBC Capital Markets, LLC
Mark A. Dwelle, CFA (Analyst) (804) 782-4008, mark.dwelle@rbccm.com

Rating: Outperform | **Closing Price: USD 50.36**
Price Target: USD 75.00 | **Implied All-in Return (%): 51.5**

Investment summary

We remain constructive on AIG and view the company as an attractive value idea in the insurance space at the current valuation. AIG's main focus is improving P&C insurance margins and repositioning the entire business for better ROEs with less earnings volatility and a more transparent business model. The company has made progress on improving core loss ratios, and we expect the trends to continue, along with profitable premium growth. In addition, the AIG 200 program is also expected to translate into further expense reduction opportunities. The initial phase of the separation of AIG's Life & Retirement segment has started (via the Corebridge IPO) and we expect additional progress on this front in 2023. Our Outperform rating reflects the following points:

Focused on underwriting margins improvement, reducing expenses: AIG has aggressively reduced exposure to underperforming lines and countries where returns are below acceptable levels. This effort along with the greater use of reinsurance, analytics, and better risk management should put AIG on a path toward improving core margins further in the years ahead. The AIG 200 program should also make AIG a more efficient and leaner company.

Favorable pricing supports growth and margin improvement: A favorable P&C pricing environment along with an improved macro backdrop should support margin improvement. Given all the heavy lifting done in past year, we expect AIG to be in a position to return to premium growth in the quarters ahead.

Capital management & balance sheet strength: We expect AIG to remain active with share buybacks that could be fueled by further stake sales in its remaining ownership interest in Corebridge. We expect further progress toward a double-digit ROE as well as efforts to improve the strength of its balance sheet (debt reduction, investment portfolio credit quality, and reserves).

Valuation

Our $75 price target is based on 0.9x our ending 2023 book adjusted value per share estimate. We utilize adjusted book value for valuation purposes (which is similar to tangible book value), as this has been management's focus in setting its ROE targets. AIG shares trade at a discount to P&C peers owing to the hybrid nature of its Life and P&C business. As the company exits this segment we anticipate some of the discount will be reduced. We expect management to continue making progress in repositioning underwriting, rightsizing expenses and investment infrastructure as well as further buybacks. As progress is made we anticipate additional multiple expansion. In our view, our price target is consistent with our Outperform rating.

Risks to rating and price target

AIG is subject to many inherent risks including market risk (interest rate risk or equity risk) that could pressure investment spreads or put pressure on investment portfolio values. There is also inherent reserving and underwriting risk mainly through whether more recent accident years prove redundant relative to expected frequency and severity assumptions. Other risk factors include: (1) P&C insurance pricing risk; (2) international risk in operating in various countries; (3) macro risks tied to its business; and (4) risks that Covid continues to linger on.

Exhibit 5 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 6 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Anheuser-Busch InBev SA/NV (BRU: ABI; NYSE: BUD)

RBC Europe Limited
James Edwardes Jones (Analyst) +44 20 7002 2101, james.edwardesjones@rbccm.com

Rating: Outperform | **Closing Price: EUR 61.33**
Price Target: EUR 72.00 | **Implied All-in Return (%): 19.0**

Investment summary

AB InBev has underperformed the sector significantly over the last five years. Some of this has been due to elements out of its control, such as turbulent currency fluctuations in Latin America, but the organic performance has also been volatile. Both factors have also led to an unappealingly large debt pile.

Currencies remain the unknown but we think AB InBev's grip on the more controllable factors is tightening. The short-term performance has been more consistent, volume growth is improving and ABI's medium-term ambition of 4-8% EBITDA growth looks realistic to us. Its regional margins are underpinned by strong competitive positioning and there might even be some upside in South America. In addition, management seems to understand the negative implications of its debt load for shareholders and has hence made the decision to pass the interim dividend in both 2020 and 2021.

Adding to the long-term investment case is the change in focus of the global beer sector; both AB InBev and Heineken are talking more about investing in the category than before. Given beer has been losing share to spirits for some time while the brewers have been distracted by M&A and underinvesting and the spirits companies have done the reverse, this change in strategy is likely to be fruitful for the brewers.

Lastly, there are additional long-term prospects of AB InBev's digital platform: 'Bees'. We think there is (rightly) nothing in the share price to reflect this at the moment, but it's an interesting piece of optionality.

Valuation

We believe that consumer staples stocks lend themselves to a DCF valuation methodology owing to the relative strength and predictability of their cash flows together with, in some instances, a significant mismatch between capital expenditure and depreciation charged through the profit and loss account, meaning that P&L-based valuation metrics (PE ratio, EV/ EBITDA ratio) can be misleading. We use a derivative of a traditional DCF calculation called adjusted present value (APV) whereby the business's operating cash flows are discounted at its cost of equity (8% in this instance) and tax shield at the cost of debt (2.9%). We assume a terminal growth rate of 2.5% per annum from 2035. Under these assumptions, we derive a fair value of €67 per share. Discounting the APV forward by a year at the cost of equity and adding in our dividend forecast for 2022 yields a 12-month price target of €72. Our price target and the implied return support our Outperform rating.

Risks to rating and price target

Further inflation and a significant deterioration in consumer confidence and employment following Russia's invasion of Ukraine would be detrimental to sales and margins. A resurgence of COVID-19 and revival of on-trade closures and lockdown in response to the outbreak of COVID-19 poses a significant threat to AB InBev. On-trade closures would affect its ability to brand-build and manage working capital. Almost all of ABI's debt is in developed market currencies (principally US$ and €s). Any delay in paying down debt (for example, as a result of emerging market currency weakness) would be unhelpful for ABI's share price. The US is ABI's largest market and its largest mainstream brands have consistently lost market share; an acceleration in this market share loss, or slowdown in the US market overall, would not be good. ABI is heavily exposed to emerging markets, notably, Brazil, China, Colombia, Mexico and South Africa. A significant deterioration in consumption or market share in these markets would be a downside risk.

Exhibit 7 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 8 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

Boston Scientific Corporation (NYSE: BSX)

RBC Capital Markets, LLC
Shagun Singh (Analyst) (646) 618-6886, shagun.singh@rbccm.com

Rating: Outperform | **Closing Price: USD 50.03**
Price Target: USD 53.00 | **Implied All-in Return (%): 5.9**

Investment summary

BSX is increasing its WAMGR by shifting into faster-growing MedTech end-markets. BSX's shift into higher adjacent growth markets via tuck-in M&A looks poised to drive its WAMGR from -1% in 2011–12 to above 6% by 2024. The key growth areas include single-use endoscopes (EXALT-D/B), prostate health (Rezum), cardiac monitors (Preventice, LuxDx), cryoablation (POLARx) and pulsed field ablation (Farapulse), neuromodulation (WaveWriter Alpha), structural heart (Accurate Neo2, Watchman), and peripheral interventional (TheraSphere, EKOS), among others. BSX's category leadership strategy driven by product innovation and M&A should drive organic revenue growth above its WAMGR (5–6%) and at the high end of its stated range (6–8%).

M&A is the #1 focus at BSX in driving category leadership. We expect BSX to continue its disciplined approach to M&A. It spent +$13B in deals and +$1B in investments across +50 companies in the last decade with +35 active investments in its VC portfolio. In 2021, BSX made six acquisitions (Preventice, Farapulse, Lumenis, Vertiflex, Devoro, and Baylis), and is committed to a BBB+ rating with gross leverage of 2.25–2.50x. BSX expects to allocate its FCF to high-quality tuck-in/adjacent M&A, and opportunistic share buybacks.

Positioned to drive consistent double-digit EPS growth. BSX has a clear pathway to consistent double-digit EPS growth driven by top-tier organic revenue growth (guidance of 6–8% organic CAGR during 2022–24) and strong annual OM expansion (+50bps annually). We project GM expansion driven by annual product cost reduction, contribution from value improvement programs, and strategies to reduce pricing pressure and COVID inefficiencies; OM driven by efficient SG&A spending and enhanced productivity in R&D spending. We expect BSX to deliver +30% OMs over time.

Upcoming potential catalysts. In AFib trials, FROzEN-AF (POLARx; 2023E study completion), ADVENT (FARAPULSE; 2023E), NEwTON-AF (StablePoint; 2023E); in heart valve, PROTECTED TAVR (SENTINEL), ACURATE Neo2 (US launch 2024E); WOLF commercial launch and PE trial; EMPOWER (leadless pacemaker) US IDE; TheraSphere geographic expansion.

Valuation

Our $53 price target is an equal blend of: (1) DCF yields a value of $56 per share and reflects our forecast through 2032 with a 2% terminal value growth rate and a WACC of 8.0%; (2) EV-to-Sales analysis uses a 2024E sales multiple of ~5.8x, which yields a value of $53; (3) EV-to-EBITDA analysis uses a 19.0x multiple on 2024E EBITDA, which yields a value of $52; and (4) P/E multiple of 24x on 2024E EPS, which yields a value of $52. Our price target of $53 supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include, but are not limited to: (1) competition that can disrupt and take share; (2) R&D efforts or clinical trials that do not materialize; (3) supply chain or manufacturing disruptions; (4) geopolitical risk; and (5) FX headwinds.

Exhibit 9 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 10 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Canadian Natural Resources Limited (TSX: CNQ; NYSE: CNQ)

Rating: Outperform	Closing Price: CAD 74.79
Price Target: CAD 89.00	Implied All-in Return (%): 23.8

RBC Dominion Securities Inc.
Greg Pardy, CFA (Head of Global Energy Research) (416) 842-7848, greg.pardy@rbccm.com

Investment summary

We rate the common shares of Canadian Natural Resources Outperform for the following reasons:

Globally Distinguished. We believe Canadian Natural Resources' management committee structure and shareholder alignment are unique factors which distinguish the company globally. CNQ's long-life, low-decline portfolio—anchored by moderate sustaining capital—affords the company superior free cash flow generative power.

Management Committee Structure. CNQ does not have a CEO. Instead, the company is stewarded by a management committee consisting of 20 people. This group meets weekly and oversees all matters spanning marketing, finance, ESG, operations, and technology, amongst others. Murray Edwards, Executive Chairman, Tim McKay, President, and Mark Stainthorpe, CFO, are all key members of the committee.

Impressive Shareholder Returns. Alongside fourth-quarter results, CNQ modified its shareholder returns policy which now revolves around a net debt floor of $10 billion (up from $8 billion previously). The company is currently allocating 50% of its free cash flow (after dividends and base capital) towards share repurchases, with the balance (less strategic growth capital/acquisitions) earmarked for debt reduction. Under its new policy, once CNQ's net debt falls to $10 billion the company will allocate 100% of its free cash flow as incremental returns to shareholders. Free cash flow will be defined as adjusted FFO less dividends and total capital expenditures (excluding A&D) in the year. To the extent that the company's net debt rises above $10 billion, it would revert to its prevailing 50/50 policy.

Valuation

Our price target of $89 per share reflects an equal weighting toward a multiple of 1.0x our NAV and an implied 2023E debt-adjusted cash flow multiple of 8.5x at mid-cycle commodity prices. The multiples we have chosen reflect CNQ's superior execution capability, long-life, low-decline asset base, and free cash flow generation potential. Our price target and implied return support our Outperform rating.

Risks to rating and price target

The most significant risk to our price target and rating is unexpected changes in crude oil and natural gas prices. Specifically, to the extent that the COVID-19 pandemic and associated social distancing measures continue to negatively impact global oil demand, it may result in CNQ realizing lower-than-anticipated sales prices for its production volumes. Other risks include the impact of foreign exchange and government legislation as it relates to royalties, income taxes, and environmental policy.

Exhibit 11 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 12 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

Canadian Pacific Railway Limited (TSX: CP; NYSE: CP)

RBC Dominion Securities Inc.
Walter Spracklin, CFA (Analyst) (416) 842-7877, walter.spracklin@rbccm.com

Rating: Outperform | **Closing Price: CAD 104.07**
Price Target: CAD 122.00 | **Implied All-in Return (%): 18.0**

Investment summary

Our positive view on CP centers on a best-in-class railroad ahead of a transformative acquisition, which we believe will set the stage for significant growth and a material upward valuation re-rate. Key points:

CP's purchase of KSC significantly improves network reach. The network advantage of the CP-KCS deal is the most compelling merit of the transaction in our view. The deal opens up new markets as well as gives CP a meaningful structural advantage versus peers. The transaction significantly increases the company's network reach from Vancouver to Saint John, and now via KCS, down to the ports of Lazaro Cardenas and Veracruz in Mexico. The new network connects six of the seven-largest metro regions in North America in a single-line connection, particularly between the Midwest US / Canada into the Gulf Coast / Mexico and a new third option between the Midwest US and Texas / Mexico.

Diversification a big component of the value proposition in KCS deal. Particularly favourable is the improvement in diversification that comes on both a business line and a geographic basis. Notable is the level of Merchandise exposure that KCS brings to CP, as well as the increased US and new Mexican revenue streams.

US$1B in potential synergies. Of particular note is the revenue synergy opportunity (US$820MM of the total) with expected share gains in Grain, Fertilizer, Intermodal, Auto, and Crude.

Valuation

Our $122 price target is based on applying a P/E multiple of 19.5x to our 2025 EPS estimate of $6.73. Our 2025 EPS forecast reflects CP achieving full synergy run-rate on the KSU acquisition in line with guidance provided when the deal was announced. The target multiple is a premium to peers, in our view warranted by CP's operations-focused management team as well as the increased network reach following the KSU acquisition. Our price target supports our Outperform rating.

Risks to rating and price target

Key risks to our positive thesis relate to the acquisition of KSU. See below for further detail:

Mexico concession risk. The two major rails in Mexico do not own their real estate and instead operate on concession from the Mexican government. The current concession expires in 2047 and was subject for review in 2027, but KCSM recently reached an agreement with the SICT that extended exclusivity rights granted to KCSM (in Mexico) for an additional period of 10 years to 2037. Management teams at both entities are of the view that if CPKC provides a high-value service offering at a competitive price, there will be no need to make major changes to the concession arrangement.

Integration risk. We consider CP mgmt to be one of the top teams in North America and have strong confidence in the ability of this team to execute on the integration of this deal and achieve (or exceed) the targets announced. Moreover, we were encouraged by the concurrent announcement that CP's Board and CEO Keith Creel have agreed to contract amendments that would see Mr. Creel lead the company out at least to 2026 (regardless of the deal going ahead or not). However, it is still possible that CP encounters unforeseen headwinds that could potentially impact forecasted synergies.

Exhibit 13 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 14 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Constellation Software Inc. (TSX: CSU)

RBC Dominion Securities Inc.
Paul Treiber, CFA (Analyst) (416) 842-7811, paul.treiber@rbccm.com

Rating: Outperform	**Closing Price: CAD 2,540.91**
Price Target: CAD 3,000.00	**Implied All-in Return (%): 18.3**

Investment summary

We believe that Constellation Software is likely to generate one of the highest returns for shareholders over the long term in our coverage universe. Our Outperform thesis reflects: (1) Constellation's ability to rapidly compound capital through acquisitions; (2) Constellation is well positioned to benefit in an uncertain macro environment; and (3) Constellation's valuation appears attractive.

Constellation's ability to rapidly compound capital through acquisitions. We believe that Constellation Software is likely to generate one of the highest returns for shareholders over the long term in our coverage universe. Our outlook reflects the compounding of Constellation's high hurdle rates, along with the scalable nature of Constellation's decentralized business model. Constellation has made changes to its business model to provide for the redeployment of capital at high rates of return. Additionally, the acquisition targets in Constellation's database continue to grow (now at 40k, up from 1.2k in 2006). The 40k acquisition targets imply a large $200B+ addressable market. Moreover, Constellation is pushing decisions for allocating capital further down into the organization. Constellation deployed a record $1,694MM capital on acquisitions in FY22, compared to $1,362MM in FY21 and just $531MM FY20.

Well positioned to benefit in an uncertain macroeconomic environment. The high frequency of acquisitions and capital deployed YTD in 2023 validate that Constellation's model is counter-cyclical. In periods of economic and financial duress, we believe that Constellation is more likely to deploy larger amounts of capital at high rates. Moreover, Constellation's software is mission critical and required for day-to-day operations. Recurring maintenance revenue accounts for 71% of FY22 revenue. Our outlook calls for Constellation's constant currency organic growth to remain stable at 3.0% FY23e and 2.0% FY24e, from 2.8% FY22.

Constellation's valuation appears attractive. Constellation is trading at 20x FTM EV/EBITDA, above Canadian software consolidators. We believe Constellation's valuation appears attractive given the company's proven ability to compound FCF/share over the long term.

Valuation

Our C$3,000 price target equates to 19x CY24E EV/EBITDA, justified above Canadian software consolidator peers in our view, given Constellation's faster ability to compound capital in the long term. Constellation has converted 84% of adj. EBITDA into FCF over the last five years. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to our rating and price target include: (1) quarterly lumpiness; (2) lack of accretive acquisition candidates; (3) unexpected organic growth headwinds; (4) an inability to sustain further margins; (5) loss of key employees; and (6) a decline in tech market valuations.

Exhibit 15 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 16 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

CrowdStrike Holdings, Inc. (NASDAQ: CRWD)

RBC Capital Markets, LLC
Matthew Hedberg (Analyst) (612) 313-1293, matthew.hedberg@rbccm.com

Rating: Outperform	**Closing Price: USD 137.26**
Price Target: USD 160.00	**Implied All-in Return (%): 16.6**

Investment summary

CrowdStrike was founded in 2011 with a mission of reinventing security for the cloud era. Co-founder George Kurtz previously worked at a gen-1 AV endpoint vendor and was motivated to build CrowdStrike after realizing that legacy security technology was incapable of protecting customers against modern attacks within a hybrid-cloud architecture.

The company developed a differentiated cloud-native security platform that leverages its lightweight intelligent agent and Threat Graph database across a multi-module portfolio of solutions. The company and its customers benefit from the network effect, as each additional endpoint added to the platform expands the crowd-sourced database, which in turn improves the quality of the algorithms.

We view CrowdStrike as a prime land-and-expand model benefiting from SaaS delivery and ability to rapidly add more modules with no extra configuration or consulting needed. The long-term power of the install base should lead to strong net expansion rates as the company cross-sells additional seats (endpoints) and modules.

Potential catalysts include: (1) ability to maintain net expansion rates by selling additional products into its growing customer base and maintaining low churn rates; (2) new product introduction and/or traction from recently introduced modules; specifically Cloud Workload protection; (3) accelerated customer additions leveraging its multi-pronged, go-to-market approach; (4) accelerated share-shift from legacy vendors; and (5) faster-than-expected progression toward profitability driven by top-line success.

Valuation

We calculate our $160 price target by applying a 12.6x EV/S multiple to CY/23E revenue of $2,980.0 million reflecting a more challenging macro environment, which remains a premium to leading growth security peers but reasonable given our LT view of growth and profitability. Our price target supports an Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) CrowdStrike operates in a market with competition from larger legacy competitors, like Symantec, as well as newer entrants; (2) potential pricing pressure given the crowded nature of the market; (3) CrowdStrike operates a land-and-expand model; failure to retain existing customers could be a detriment; (4) CrowdStrike has experienced rapid growth; failure to manage growth/expectations could cause operational challenges; and (5) COVID-19 could impact company operations or customer demand.

Exhibit 17 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 18 - Forward consensus EV/sales history



Source: Factset

Most recent company note: link

CSL Ltd. (ASX: CSL)

Royal Bank of Canada, Sydney Branch
Craig Wong-Pan (Analyst) 612 9033 3189, craig.wong-pan@rbccm.com

Rating: Outperform	Closing Price: AUD 287.73
Price Target: AUD 352.00	Implied All-in Return (%): 23.6

Investment summary

Leader in attractive market. CSL is a well-run company with a market-leading position in plasma-derived therapies. The plasma-derived therapeutics industry is attractive to operate in given strong patient demand, the product is difficult to replicate, there are high barriers to entry and products do not face patent cliffs. CSL has a particularly strong position in the Ig market, which has been growing at 12% CAGR.

Strong pipeline of R&D assets. CSL has a large number of pipeline assets. We do not include any of these pipeline assets in our forecasts but estimate successful commercialisation of CSL112 could be worth an NPV of A$24.0bn.

Potential catalysts include: (1) positive updates on CSL112; and (2) strong plasma collection growth.

Valuation

We value CSL using a DCF methodology with a 5.4% WACC, a 0.92 beta and a 3% terminal growth rate. We convert CSL's discounted US-denominated cashflows into an AUD price target using a 0.69 AUD/USD rate. Our A$352 price target supports an Outperform rating and is based on: (1) revenue growth of Ig 9% and albumin 7%; (2) Haemophilia A revenues growing 3% per annum; (3) HAE sales decline 1% per annum; (4) Vifor's product revenues decline 50% after patents expire; (5) an R&D/sales ratio of ~10%; and (6) a selling & marketing/sales ratio of ~11.5%.

Risks to rating and price target

Risks to rating and price target include: (1) successful development and commercialisation of blockbuster drugs, such as CSL 112 and Hemgenix; (2) significant changes in donor fees; (3) COVID outbreaks or lockdowns in the US leading to limited plasma collected; (4) competitor products launched that take market share from CSL, such as anti-FcRn, haemophilia A gene therapies, HAE gene therapies; and (5) better or worse sales performance following Vifor's patent expiries.

Exhibit 19 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 20 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Diamondback Energy Inc. (NASDAQ: FANG)

RBC Capital Markets, LLC
Scott Hanold (Analyst) (512) 708-6354, scott.hanold@rbccm.com

Rating: Outperform | **Closing Price: USD 135.17**
Price Target: USD 182.00 | **Implied All-in Return (%): 43.4**

Investment summary

We believe FANG shares should outperform its peer group over the next 12 months. Management has built a solid Permian Basin position with a deep inventory of liquids-rich development opportunities. The company is one of a few that have amassed a combination of quality assets, strong economic growth, minerals ownership, and a water business, which collectively help to provide a competitive advantage. We believe FANG has one of the lowest cost structures in the basin and a corporate cash flow break-even (including dividend) that is among the best in the industry.

A shareholder-friendly return proposition that includes at least 75% of FCF in the form of a fixed dividend, variable dividend, and stock buybacks. Management plans to be opportunistic on buybacks when FANG shares trades at or below the implied mid-cycle valuation ($60-65/bbl based).

The company has a runway of tier-1 inventory projects that extend more than a decade.

FANG has a track record of achieving its growth targets while spending within cash. It has a willingness and demonstrated ability to adjust activity levels quickly in response to challenging market conditions.

ESG is expected to play a continued focus in FANG's corporate strategy.

Valuation

Our $182/share price target is derived from a combination of evaluating forward EBITDA multiples, and our Net Asset Value (NAV). Our price target reflects: (1) a premium to our Net Asset Value (NAV), reflecting higher near-term commodity prices, similar to peers. Our NAV is a risked assessment of 3P reserves using the long-term RBC commodity price outlook of $65/bbl (WTI), $70/bbl (Brent), and $3.75/Mcf (HH); and (2) a 4.8x multiple on our 2023 EBITDA estimate, fairly in line with peer EBITDA multiples.

Our price target along with FANG's robust shareholder return strategy support our Outperform rating.

Risks to rating and price target

Much of the potential in FANG shares relies on executing its development strategy on its unconventional acreage positions. Results below expectations in this area would have an adverse effect on the stock. Weaker-than-expected commodity prices could cause the stock to perform below our expectations and impede achievement of our price target objective.

Exhibit 21 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 22 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

DuPont de Nemours, Inc. (NYSE: DD)

RBC Capital Markets, LLC
Arun Viswanathan, CFA (Analyst) (212) 301-1611, arun.viswanathan@rbccm.com

Rating: Outperform	**Closing Price: USD 71.77**
Price Target: USD 92.00	**Implied All-in Return (%): 29.9**

Investment summary

Multiple expansion opportunity as a multi-industrial company. Given we believe DuPont's valuation multiples could increase 2–3x should DuPont successfully market itself as a multi-industrial company, valuation multiples could move higher. DuPont notes that when comparing against other multi-industrial companies (MMM, HON, and ITW), DuPont provides similar-in-class benchmarks.

Further divestment plans post COVID-19. Considering Chairman Ed Breen's successful divestment cases at Tyco when he was CEO of that company, we believe DuPont will continue assessing its portfolio to divest unaligned businesses in order to deliver shareholder value.

Valuation

We value DD on a forward EV/EBITDA basis using 2023E. We apply a 15.0x multiple to our 2023E EBITDA of $3.17B (which includes recent M&A, announced share buybacks and divestitures) to arrive at a price target of $92/share. Despite the raw materials pricing headwind, given the portfolio transformations and buybacks, we believe DD should trade at the high end of its historical 9-16x multiple range. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) slower-than-expected cycle recovery in China and North America; (2) synergy/integration challenges; (3) further delays or failure to optimize spin strategy; and (4) further demand deterioration from COVID-19 impact.

Exhibit 23 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 24 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Element Fleet Management Corp. (TSX: EFN)

RBC Dominion Securities Inc.
Geoffrey Kwan , CFA (Analyst) (604) 257-7195, geoffrey.kwan@rbccm.com

Rating: Outperform	**Closing Price: CAD 17.75**
Price Target: CAD 27.00	**Implied All-in Return (%): 54.4**

Investment summary

Why we rate EFN shares Outperform: Four key themes drive our positive view of EFN: (1) **attractive growth –** We forecast that EFN's EPS could grow at a mid-teens CAGR over the next five years, driven by new client wins, organic growth within existing customers, and significant returns of capital; (2) **multiple potential catalysts** (see below); (3) **strong defensive attributes** – EFN faces minimal credit/residual risks and tends to have long-term contracts (3–5 years) with high retention rates (~99%); and (4) **attractive valuation** – we see high EPS growth as a key driver of valuation and potential valuation multiple expansion.

Why we like the fleet management industry: In our view, the fleet management industry has several attractive attributes, which we think, given that EFN is the largest player in North America, should provide outsized benefits to the company. Specifically: (1) the fleet management industry has high barriers to entry, which we think is partly attributable to high switching costs for customers, but also significant scale benefits; (2) the industry has a favorable competitive landscape, which we think has generally resulted in rational pricing behavior; (3) as mentioned above, the industry benefits from long-term contracts and very low client turnover/churn; and (4) the industry has strong free cash flow generation potential.

Potential catalysts include: (1) stronger origination volumes; (2) new customer wins and cross-selling existing customers new fleet services; and (3) increased returns of capital (e.g., further dividend increases, share buybacks, etc.).

Valuation

Our 12-month price target is $27/share. Our 12-month price target is based on applying an 18x multiple to our blended 2024E/2025E fully diluted operating EPS forecast of $1.52, which is a premium to the global fleet manager peer average. We believe a premium to global fleet management peers is warranted given factors including higher expected growth, stronger fundamentals, greater scale, and very little exposure to credit risk. Our target multiple reflects an attractive mix of strong positive fundamentals, attractive growth potential even in a recession scenario, potential catalysts (e.g., earnings upside) and defensive attributes. We believe our 12-month price target and the implied total return support our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) evidence of further delays to the time of normalizing originations/OEM production past mid-2023 (EFN's current guidance); (2) key customer losses; and (3) key personnel departures.

Exhibit 25 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 26 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Ferrari N V (MILAN: RACE)

RBC Europe Limited
Tom Narayan (Analyst) +44 20 7429 8594, tom.narayan@rbccm.com

Rating: Outperform	**Closing Price: EUR 249.30**
Price Target: EUR 283.00	**Implied All-in Return (%): 13.9**

Investment summary

Production increase on the horizon. The launch of new vehicles like the Roma and the Purosangue should enable Ferrari to penetrate new demographics and the substantial Chinese luxury auto market. Ferrari is likely, in our view, to dramatically expand its production. It has the capacity to make 15,000 vehicles but currently makes only 10,000.

Ferrari is a luxury stock. Ferrari's EBITDA margins, stock price movements, and customer base are more similar to those of luxury stocks than auto OEMs. More than 40% of Ferrari owners already have at least one Ferrari and customers are largely in the growing UHNW (ultra-high net worth) and millionaire segment, similar to high-end luxury products. Furthermore, like some luxury brands, Ferrari has pricing power and loyalty, especially given the aura of exclusivity that it has garnered among its customers.

Ferrari has an electrification strategy. We don't envision a scenario where Ferrari sells 10,000 units in Europe (threshold where it begins to pay fines). Moreover, Ferrari is already using electric technology to enhance performance and expects EV mix to reach 80% of vehicle sales by 2030. Longer term, we believe Ferrari can fully electrify its fleet.

Potential catalysts include: (1) Purosangue launch; (2) growth of UHNW and millionaire demographic; and (3) electrification trends in Europe.

Valuation

Our €283 price target is derived by applying a 24.5x multiple to our 2024E EBITDA. This multiple is derived using DCF value. We then add Industrial net cash, subtract underfunded pension liabilities, and discount back at 7% to arrive at our equity value. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) challenges to penetrating China; (2) electrification is not in Ferrari's DNA; and (3) premium SUV market is already hyper-competitive.

Exhibit 27 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 28 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

HEICO Corporation (NYSE: HEI)

RBC Capital Markets, LLC
Ken Herbert (Analyst) (415) 633-8583, ken.herbert@rbccm.com

Rating: Outperform	**Closing Price: USD 171.04**
Price Target: USD 190.00	**Implied All-in Return (%): 11.2**

Investment summary

HEICO is a high-quality A&D supplier. The company generates above-industry margins and its FCF conversion ranks consistently as some of the highest in the industry. Moreover, HEI has delivered ~20% top-line growth for several years, making it a long-time A&D favorite for growth investors. We believe the company identified an inefficiency in the commercial aerospace AM (PMA parts) and has built a strong commercial AM and defense electronics set of capabilities.

As the industry recovers, we believe there is a long runway for HEI's commercial business. For example, as fleets age in emerging markets and China, we believe the demand for alternative aircraft parts will increase. The pace may not be the same as it has been in established markets in North America, Europe, and North Asia, but we believe the fundamentals will support the gradual adoption of PMA parts globally. HEI does face competition from OEMs, but it remains disciplined on its PMA and DER selection process. Moreover, the company is well positioned for continued share gains in its commercial aerospace offering as the aviation industry continues to recover.

Key catalysts for HEI include potential M&A transactions and quarterly upside surprises relative to conservative estimates. We also believe that investors will be focused on the quarterly cadence of aerospace sales.

Valuation

Our $190 price target is based on a blend of 50x our 2024E P/E and 33x our 2024E EV/EBITDA. We believe multiples at the mid-to-upper end of the historical ranges are appropriate considering that we are in the mid-stages of the anticipated aerospace recovery, and the company should see incremental upside from acquisitions, not yet reflected in estimates. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) pace of the air travel recovery and impact of COVID-19 variants on business and leisure air travel; (2) supply chain disruptions and material lead times; (3) ability to hire the necessary human capital to support growth objectives and opportunities; (4) airline maintenance spending plans and overall airline financial health; (5) airline and aircraft part distributor inventory levels; (6) airline deferred maintenance plans and availability and pricing of new and used space parts and material; (7) total defense spending levels for both modernization efforts and legacy defense systems; (8) timing and opportunity for foreign military sales; (9) risk to FY23 defense budget contract awards and appropriation delays; (10) pace of new company product and service introductions; (11) pace and successful integration of future M&A activity; (12) cost management and free cash flow generation; and (13) interest rates and the ability to access capital to support acquisition and other growth initiatives.

Exhibit 29 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 30 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Inditex (MADRID: ITX)

RBC Europe Limited
Richard Chamberlain (Analyst) +44 0 20 7429 8092, richard.chamberlain@rbccm.com

Rating: Outperform | **Closing Price: EUR 30.90**
Price Target: EUR 32.00 | **Implied All-in Return (%): 7.8**

Investment summary

We view Inditex as a strong omnichannel fashion retailer, which historically has benefited from its speed to market and product department-driven manufacturing process. In recent years it has become more integrated between stores and online, helped by its centralised inventory pool, RFID rollout and increasing ship from store.

We favour Inditex's longer-term FCF improvement story, with a strong track record for control over working capital and lower capital intensity. This should give investors confidence that Inditex can sustain a strong and growing dividend long term.

Inditex has historically generated a strong ROCE, which we expect it should be able to maintain at over 20%.

Inditex's strong sales densities have enabled it to earn a mid- to high-teens margin historically, which we think it can maintain.

Potential catalysts:

Inditex will report its Q1 on June 7. We see potential for it to beat consensus on top line, driven by strong collections, more productive space and as we expect Inditex to continue to offer strong fashion and value for money for customers. We model LFL sales +10% yoy for Q1 and +7.5% yoy for FY24e. On gross margin, Inditex has maintained its "stable" (+50/-50 yoy) guidance, and we model -100bps yoy for Q1 and -15bps yoy for the full year, due to fx (EUR/USD). We expect the drag on financial charges to ease off over time. Inditex has guided to growth in gross space of 3% for FY24, and we model around half flows through to net contribution to sales, with a -1pp currency impact on sales. Capex is expected to be EUR1.6bn for the year.

Valuation

We use a DCF analysis to arrive at our price target for Inditex of EUR32, which supports our Outperform rating on the shares. We assume a 10-year sales CAGR of c.4.5% and an operating margin of c.17.5% in the terminal year. We use a WACC of 7.75%, and a terminal growth rate of 2% to account for Inditex's global reach and expansion prospects in fragmented apparel markets worldwide.

Risks to rating and price target

We believe Inditex has potential to achieve at least high-single-digit EPS growth on a constant-currency basis longer term. We could see downside risk to estimates due to macro or geopolitical challenges in key markets, but the competitive environment in global fashion looks fairly stable. Inditex is also leveraged to the euro exchange rate versus a basket of other currencies; a stronger EUR has in the past caused negative translation and gross margin mix effects, due to Inditex pricing higher outside the Eurozone and having a relatively high proportion of costs in euros.

Exhibit 31 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 32 - Forward consensus P/E history



Source: Factset

Most recent company note: link

London Stock Exchange Group plc (LSE: LSEG)

RBC Europe Limited
Ben Bathurst (Analyst) +44 20 7429 8910, ben.bathurst@rbccm.com

Rating: Outperform | **Closing Price: GBp 7,868.00**
Price Target: GBp 10,200.00 | **Implied All-in Return (%): 31.2**

Investment summary

Following the completion of the Refinitiv deal, LSEG has transformed into an enlarged group with higher quality revenue streams and enhanced exposure to secular growth themes.

We expect the diverse, mostly recurring, revenue streams of the enlarged group to convert to strong cash generation over all time horizons, and we expect leverage to reduce to 1.6x by Dec-23.

Surplus cash generation may be used to buy back shares from Thomson Reuters & Blackstone (as announced with the intended £750m directed buyback), reduce debt further, increase shareholder returns, and, as would be our preference, to invest in the range of strategic initiatives that the group has outlined, presenting a source of upside potential to our EBITDA estimates for outer years.

We argue that the transaction changes the most relevant peer group to information service providers. Compared to this peer group, LSEG stands out as trading at a discount to sub-sector averages in P/E and EV/EBITDA terms, despite having stronger than average expected earnings growth.

Improving cyclical factors and re-deployment of surplus cash from 2023 onwards are both sources of potential upside to our estimates.

Valuation

Our price target for London Stock Exchange Group (LSEG) is derived from a discounted cash flow model. We use a three-stage model, whereby we apply a Risk Discount Rate of 8% (reflecting our view of the relative risk of LSEG's business model) and a terminal value growth assumption of 3%. We model our DCF on a reported basis, incorporating FX adjustments to our earnings. We also deduct FY22 net debt of £6.226bn to reach our Equity Value.

Our price target implies a FY 2023E P/E of 30x, which we see as justified given LSEG's strong FCF generation and exposure to structural growth markets. Our price target of 10,200p supports an Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) failure to integrate with Refinitiv efficiently could produce lower revenue synergies than expected at a higher cost; (2) competition in each of its three business areas could lead to a decrease in LSEG's market share in the respective areas; and (3) Brexit uncertainty remains for Post Trade businesses as only temporary CCP equivalence has been granted to the UK clearing houses until 2025. Although we believe it is unlikely that the European Commission will completely remove all exposure to UK CCPs, this extreme outcome could impact approximately 6% of SwapClear notional.

Exhibit 33 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 34 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Lonza Group AG (SWX: LONN)

RBC Europe Limited
Charles Weston, CFA (Analyst) +44 20 7429 8425, charles.weston@rbccm.com

Rating: Outperform | **Closing Price: CHF 547.40**
Price Target: CHF 760.00 | **Implied All-in Return (%): 39.5**

Investment summary

Market trends to remain robust. The pharma market is growing at 6-7% pa and ongoing trends towards manufacturing outsourcing and onshoring will drive the CDMO market growth into the high single digits, in our view.

Lonza is positioned at the premium end of the market. Lonza is the largest and one of the most profitable CDMOs globally, deriving over half of its revenues from biologics, which we expect to grow faster than the overall market, and 10% from cell and gene therapy, which could grow in the high-teens pa beyond 2023, in our view.

Enhanced focus and transparency complemented by a strong balance sheet. Having divested its Water Care business in 2019 and its Specialty Ingredients division in 2021, Lonza is focused on pharma manufacturing, and the divestments have left the balance sheet with CHF0.2bn of net cash (end-'22), providing for ample strategic flexibility to invest. With an undergeared balance sheet and CHF10bn of pre-capex FCF 2023E-28E, the company is initiating a CHF2bn buyback at levels lower than our fair value.

High ROIC implies upside to consensus. Our proprietary capex project model indicates almost 20% upside to consensus revenue and EBITDA for 2026 — this is the key reason we are ahead of consensus forecasts.

Financials. We project that Lonza will average 14% revenue growth 2024-2027 with a 16% EBITDA CAGR as margins are less diluted from growth projects.

Valuation

The median 'EEG' of CDMO peers is 1.5x (i.e., EV/EBITDA divided by EBITDA growth) — we apply this to our forecast 15% underlying estimate of EBITDA growth, implying 22.5x EV/EBITDA, which leads to our 12-month price target of CHF760. This is roughly equivalent to our DCF calculation at a cost of equity of 8.5% and terminal growth of 3.0%. This price target supports our Outperform rating.

Risks to rating and price target

Overcapacity. Many organisations are investing into biologic production, which could lead to price competition. Our analysis suggests that this is unlikely to be an issue in the foreseeable future, but it remains a perceived risk.

Delays to ramp-up. Should the company be unable to drive volumes through its new capacity, revenue and margin will both be at risk.

Funding constraints by customers. There are already signs of a thaw in the biotech IPO market, but if the reality or perception of a tougher funding environment drives deferrals of R&D by biotechs, the pipeline of products for CDMOs may slow.

Alzheimer's outsourcing. Lonza is not a manufacturer for the new Alzheimer's drug, aducanumab, as far as we understand, but should Biogen/Eisai need to scale capacity, or another drug for this large unmet medical need come to market, this could be a substantial driver of additional demand, leading to upside risk to forecasts.

Exhibit 35 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 36 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

M&T Bank Corporation (NYSE: MTB)

RBC Capital Markets, LLC
Gerard Cassidy, CFA (Analyst) (207) 780-1554, gerard.cassidy@rbccm.com

Rating: Outperform | **Closing Price: USD 119.57**

Price Target: USD 183.00 | **Implied All-in Return (%): 57.1**

Investment summary

We rate MTB shares Outperform for the following key reasons:

Best-in-class management team: M&T Bank Corporation's management team has led the company through more than 15 years of consecutive quarters of profitability.

People's United Financial, Inc. (PBCT) acquisition: M&T's acquisition of PBCT had modest tangible book value dilution but due to the expected long-term solid earnings accretion, it should drive long-term shareholder value.

Allocation of capital: We continue to believe the company is one of the best managers of capital among the top 20 banks. M&T's estimated Common Equity Tier 1 (CET1) ratio was 10.6% in 4Q22 versus 10.7% in 3Q22. In July M&T announced a $3.0 billion stock repurchase program. In 4Q22 MTB repurchased $600 million in common stock.

Strong balance sheet: M&T proved during the last recession and financial crisis that it has a very strong balance sheet. M&T was one of only two of the top 20 banks that did not cut or eliminate its dividends over the last 15 years.

Superior underwriting standards: The company's net charge-off (NCO) ratios have consistently been below its peer group for the past 10 years.

Low-cost provider of bank products: M&T recognizes that it operates in a commodity business and therefore strives to be the low-cost provider of bank products in its markets. Its efficiency ratio (total operating expenses divided by total revenues) has consistently been the lowest among the top 20 banks.

Long-term investors rewarded: MTB's stock price has outperformed the S&P 500 and the S&P 500 bank indices in each of the last 10 and 20 year time periods. The outperformance can be attributed to the company's focus on growing tangible book value and dividends per share.

Valuation

Our price target of $183 is 10.6x our 2023 EPS estimate, 1.20x 2Q24E book value, and 1.95x 2Q24E tangible book value. These multiples are consistent with the highest quality banks in the peer group. Our price target primarily reflects our profitability and risk assessment of the company relative to a peer group of similar companies, as well as current market concerns regarding an economic slowdown. Our price target and implied return support our Outperform rating.

Risks to rating and price target

We believe excessive monetary tightening by the Federal Reserve, which results in driving the US economy into a deep recession in 2023, is the key risk for the company, our rating and price target. A deep recession would bring on elevated levels of credit losses which would depress earnings.

Exhibit 37 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 38 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Mastercard Inc. (NYSE: MA)

RBC Capital Markets, LLC
Daniel R. Perlin, CFA (Analyst) (410) 625-6130, daniel.perlin@rbccm.com

Rating: Outperform	Closing Price: USD 363.41
Price Target: USD 392.00	Implied All-in Return (%): 8.4

Investment summary

We believe MA is a core long-term holding and an “indexed” way to play payments and benefit from three global secular mega-trends including: (1) global consumption; (2) global digitization of payments; and (3) global innovation, which is creating new payment flows.

We note that ~67% of its TAM is from new payment flows, beyond the classic cash to card conversion, while we forecast service revenues to grow 2x the carded-market and are heavily focused on cyber-intelligence/security and data analytics/services, both long-term secular themes.

Assuming a more normalized macro spending environment, which includes a resumption of travel spending, we estimate ~$1B of incremental revenues are embedded in the model.

Valuation

Our price target of $392 is 32x our CY23 EPS estimate, generally in line with its historical average. Underlying our estimates are expectations for: (1) near-term pressure before a rebound to double-digit growth in purchase volumes, with modest pricing and secular growth; (2) double-digit increases in transaction revenues; (3) near-term pressure on cross-border revenue growth; and (4) relatively flat client incentives as a percentage of gross revenues. Our price target supports our Outperform rating.

Risks to rating and price target

A slowdown in payment volumes and cross-border travel, increased regulatory scrutiny or a pushback from large financial institutions on pricing could impede our price target and rating.

Exhibit 39 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 40 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Meta Platforms, Inc. (NASDAQ: META)

RBC Capital Markets, LLC
Brad Erickson (Analyst) (503) 830-9488, brad.erickson@rbccm.com

Rating: Outperform | **Closing Price: USD 211.94**
Price Target: USD 225.00 | **Implied All-in Return (%): 6.2**

Investment summary

In possessing both the largest user base as well as the deepest amount of knowledge (data) of that user base, we believe META can compound 15–20%+ earnings growth once it gets through its currently elevated investment cycle around AI which is aimed to both drive engagement share gains while also restoring it to being the dominant player in social media with structural advantages around ad targeting.

Valuation

Meta trades at a discount to the broader internet group, which is largely a function of views around core market maturity and laws of large numbers. This discount is likely to persist given the undeniable size of the core business, but the gap should persist or narrow depending on META's ability to demonstrate stability in its ad business relative to the Apple-related disruption around signal loss.

Our $225 price target supports our Outperform rating and is based on 10x EV/'23E EBITDA and 22x P/'23E EPS. Our target multiples are below the peer group due to high market penetration and sheer size but in our view reasonable for the LT secular growth and compounding earnings power of the core business.

Risks to rating and price target

These include regulation, user privacy mandates implemented by either governmental agencies or competing ecosystem providers, competition from existing social platforms or potentially other large technology players, public perception that could lead to a decline in usage, and a macroeconomic downturn.

Exhibit 41 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 42 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

Palo Alto Networks, Inc. (NYSE: PANW)

RBC Capital Markets, LLC
Matthew Hedberg (Analyst) (612) 313-1293, matthew.hedberg@rbccm.com

Rating: Outperform | **Closing Price: USD 199.74**

Price Target: USD 216.00 | **Implied All-in Return (%): 8.1**

Investment summary

Palo Alto Networks is a provider of next-generation network and endpoint security. The company should be able to grow into a growing network and endpoint security market by expanding within its customer base while increasing its reach to new customers through a larger portfolio, geographical expansion, and share shift. We view Palo Alto as well positioned to benefit from an increasingly complex security and threat landscape and as an industry leader in security.

Growth drivers include: (1) above-market growth opportunity by taking share from legacy security vendors; (2) land, expand, and retain strategy for maximizing value from existing install base; (3) potential market gains from a disruptive subscription business; (4) international growth opportunities; (5) opportunity for margin expansion through economies of scale; and (6) benefits from the increased focus on data security due to ongoing breaches and increased regulation.

Valuation

Our $216 price target assumes that shares trade at an EV/FCF multiple of 30x our CY/23 estimate, a slight premium to LC peers. Our price target and multiple reflect our confidence in the momentum of next-gen billings and durability of network security given improved consistency as well as new visibility provided for the strategic outlook. On an EV/recurring revenue basis, our price target reflects 10x our CY/23 estimate, in line with similarly growing peers. The implied return to our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) improvements around the product line and impact from sales incentives to drive product growth are taking longer than expected; (2) the macro environment remains uncertain; although the security market remains robust, a slowdown in global activity could hinder results; (3) dependency on channel partners is significant and concentrated among several large global distributors; (4) Palo Alto could face increased competition as it continues to take share either from legacy providers or new entrants to the security market; and (5) the company could encounter operational difficulties as it attempts to continue to rapidly increase in scale.

Exhibit 43 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 44 - Forward consensus EV/sales history



Source: Factset

Most recent company note: link

PG&E Corporation (NYSE: PCG)

RBC Capital Markets, LLC
Shelby Tucker, CFA (Analyst) (212) 428-6462, shelby.tucker@rbccm.com

Rating: Outperform | **Closing Price: USD 16.17**
Price Target: USD 20.00 | **Implied All-in Return (%): 23.7**

Investment summary

In the long term, we see significant upside potential if the company is able to execute on its plans and improve investor and rating agency confidence. Near-term, we believe a discounted P/E multiple is warranted due to an untested AB 1054, though this should provide better protection relative to the past. Any potential for further material wildfire liabilities could sour regulators and politicians. Our Outperform rating is predicated on a reasonable application of AB 1054 during this wildfire season, should the need arise, which should allow some of the discounted stock valuation to subside.

Potential catalysts:

Execution of plan under new management. Execution of the company's Lean Operating System (LOS) and wildfire plans will be essential in terms of improving the company's perceived risk profile, which could lead to greater confidence from investors and rating agencies.

Upside to capital expenditure program. Current capital forecasts include spend above authorized amounts. Potential recovery of these investments in the future may result in greater rate base growth. Approval of undergrounding wiring would provide a boost of confidence.

CA regulatory environment. Constructive outcomes for rate cases as well as approval of additional capital investments may accelerate growth at the utility.

CA emissions targets and electrification. Statewide emissions goals as well as local efforts to decarbonize may promote electric systems over gas systems, resulting in impacts on gas customer counts.

Reintroduction of a dividend. We expect PCG to start paying a dividend after 3Q23. This should prompt income investors to add PCG to their portfolios.

Valuation

We arrive at our $20 price target by applying a 15.0x P/E to our 2024 EPS estimate. Our target multiple is a material discount to our base electric target P/E multiple of 19.4x, which we believe is warranted due to an untested AB 1054 and the potential selloff of Wildfire Fund shares. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) negative change in California regulatory environment; (2) additional fines or penalties that are unexpected related to safety matters; (3) utility causes large-scale wildfire; (4) unplanned reduction in the capital spending program; and (5) CA electrification efforts result in fewer gas customers.

Exhibit 45 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 46 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Restaurant Brands International Inc. (NYSE: QSR)

RBC Capital Markets, LLC
Christopher Carril (Analyst) (617) 725-2109, christopher.carril@rbccm.com

Rating: Outperform | **Closing Price: USD 67.14**

Price Target: USD 81.00 | **Implied All-in Return (%): 23.3**

Investment summary

We continue to view QSR as our top pick among the global franchised fast food group. We see potentially improving Burger King US trends, accelerating development and shifts in capital allocation (toward growth investments and reduction in leverage) driving stock performance. We believe relative valuation for QSR remains compelling (~17x 2024E EBITDA, versus global peer average of ~18x), particularly as we are taking a more cautious stance on the overall group.

Potential catalysts include: (1) an acceleration in same-store sales growth, with particular focus on stability at Burger King US; (2) improvement in TH contribution to overall EBITDA growth; (3) a significant brand acquisition; and (4) accelerating new unit development.

Valuation

Our price target of $81 is based on an 18x multiple, which is in line with QSR's peer group (e.g. MCD, YUM, DPZ) average, applied to 2024E EBITDA of ~$2.7B. Our price target equates to ~24x 2024E EPS and a 5.1% FCF yield. We believe QSR deserves a multiple closer to in line with the peer group average given its continued momentum at Tim Hortons Canada, stable trends at Burger King, solid unit growth (historically >5%) and M&A optionality. Its among best-in-class dividend yield also supports our valuation. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) COVID-19-related risks may continue to impact top-line, margins, and cash flow longer than expected; (2) as with most restaurant company stocks, worse-than-expected same store sales can negatively impact valuation. Risk factors for same store sales include: macro/consumer headwinds; increased competition; declining consumer demand for the brand. In the case of QSR, we see particular attention in the near term paid to SSS of the Tim Hortons brand; (3) unit growth—a key long-term top-line driver for the company—could be impacted by increasing competition for real estate, changes in development costs or from shifts in overall demand for the brand; (4) interest rates can also affect valuation for highly/all-franchised restaurant models, particularly those with higher levels of leverage; and (5) for global restaurant companies, foreign currency exchange risk can have a meaningful impact on revenue and earnings.

Exhibit 47 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 48 - Forward consensus P/E history



Source: Factset

Most recent company note: link

S&P Global Inc. (NYSE: SPGI)

RBC Capital Markets, LLC
Ashish Sabadra (Analyst) (415) 633-8659, ashish.sabadra@rbccm.com

Rating: Outperform | **Closing Price: USD 344.77**
Price Target: USD 434.00 | **Implied All-in Return (%): 26.9**

Investment summary

We believe that the strategic INFO acquisition should accelerate the normalized revenue growth profile and deliver double-digit earnings growth driven by upside to revenue and cost synergies. Complementary data assets powered by Cloud and AI/ML should enable predictive actionable insights from disparate data assets and distribution at scale. Importantly, the transformative acquisition should propel SPGI's ESG offerings and private company offerings. Separately, SPGI guided to $12bn+ of share repurchases in FY22 along with near-term cost takeout initiatives that could drive upside to FY23E EPS.

Valuation

Our price target of $434, which supports our Outperform rating, is based on ~33x our FY23E EPS, in line with the two-year average, as the diversified business model, accelerated cost takeout, and large share repurchase help to limit downside risk to earnings posed by recent weakness in credit issuance.

Risks to rating and price target

Risks to rating and price target include: (1) a significant decline in credit issuance; (2) increased competition for market data; (3) slowdown in demand for Platts; (4) challenges in integrating acquisitions; and (5) decline in AUM linked to SPGI indices.

Exhibit 49 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 50 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Siemens AG (XETRA: SIE)

RBC Europe Limited
Mark Fielding (Analyst) +44 20 7002 2128, mark.fielding@rbccm.com

Rating: Outperform | **Closing Price: EUR 149.34**
Price Target: EUR 160.00 | **Implied All-in Return (%): 9.5**

Investment summary

Siemens has become a simpler business over the last 10-15 years, but all the change has made past performance hard to understand. We have analysed in detail the underlying performance of the continuing "new" Siemens over the last 15 years. This shows above sector growth and margin progress across the cycle, and one of the most resilient companies in downturn phases. This does not tally with a continued sector P/E discount of 15-20%.

Outperforming the sector through the cycle: Our analysis shows that "new" Siemens has not just outgrown "old" Siemens since 2006, but also the sector. It has delivered a 2006-21 sales CAGR of +4.2% vs the sector +3.6% and old Siemens +2.9%. And profit margins have risen by ~500bps such that the Industrial business is slightly better than the sector average. This supports our base case for ongoing growth in the 5-7% target range and further margin expansion.

And "new" Siemens is resilient in downturn phases: While our base case is for further positive progress, given wider geo-political concerns we also considered recessionary risks. Our modelling of the new Siemens industrial business shows it is much less cyclical than average for our coverage. Over the past three industrial downturn phases since 2007 its sales have never fallen by more than -2% and its margins by less than 100bps. This is versus a sector average -7% sales fall and 160bps margin decline.

Valuation

We value Siemens on a target P/E of 17x 23E, which is slightly above our sector average given our analysis shows Siemens continuing business as a through cycle outperformer versus the sector from an operational standpoint. It gives a valuation of €160 per share. P/E is a fair multiple to use in our view given the complicated nature of the group and its underlying net debt / EBITDA being at ~1x in line with the sector average. Our price target supports our Outperform rating on the stock.

Risks to rating and price target

Economic cycle: Siemens continues to see growth reflecting its strong order backlog, but if the macro backdrop was to worsen it could impact this assumption.

Cost flexibility: Siemens' size, complexity and board-level representation from labour unions mean that it has historically not been very agile with its cost basis. Siemens has been changing this, but it remains a factor.

Supply chain: There continue to be supply chain constraints. Siemens' outlook assumes some continued normalisation, which if it did come through would be negative.

Sector de-rating: Further concerns of a deep recession could precipitate a general sell-off and de-rating in the industrials sector, thus affecting Siemens' valuation.

Siemens could suffer indiscriminate buying/selling pressure: Siemens is a highly liquid proxy for industrial Europe and could be bought or sold by portfolio managers wanting to increase or reduce European industrial or European cyclical exposure. The share is also a major component of Germany's DAX Index.

Covid-19 impact: The business is now largely recovered, but any renewed lock downs (eg in China) could still be a further negative. Short-cycle businesses (DI and SI) have seen challenges, most notably in China, Germany and Italy.

Exhibit 51 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 52 - Forward consensus P/E history



Source: Factset

Most recent industry review: link

TELUS Corporation (TSX: T; NYSE: TU)

RBC Dominion Securities Inc.
Drew McReynolds , CFA, CA, CPA (Analyst) (416) 842-3805, drew.mcreynolds@rbccm.com

Rating: Outperform	**Closing Price: CAD 26.83**
Price Target: CAD 33.00	**Implied All-in Return (%): 28.4**

Investment summary

We view 2022 as a pivotal turning point for TELUS as the company transitions into a new post-FTTH build / 5G phase. The provision of 2023 guidance confirms that the company has emerged with a distinctively different financial and operating profile relative to most global telecom peers. With FTTH coverage reaching ~85% of the targeted broadband footprint, enhanced capex flexibility should enable TELUS to capitalize on 5G without meaningful capital constraints, opportunity costs or FCF impairment. Longer term, under certain competitive and regulatory conditions, we continue to see strong strategic and financial rationale for TELUS to explore a transformational re-organization that can fully unlock the value of core infrastructure assets and core technology assets.

Potential catalysts include: (1) greater-than-expected wireline subscriber traction driven by FTTH expansion; (2) better-than-expected efficiencies and operating leverage resulting in higher margins; (3) an easing of Alberta headwinds resulting in improved business market performance; (4) stronger-than-expected improvement in wireless ARPU growth; (5) greater-than-expected step-down in consolidated capex intensity over the medium term; and (6) the crystallization of TELUS Health and/or TELUS Agriculture & Consumer Goods.

Valuation

The implied total return to our $33 price target supports our Outperform rating. To derive our target, we take the average of three approaches: (1) applying a 21.0x multiple to our blended two-year forward adjusted EPS estimates; (2) applying a target EV/EBITDA multiple of 8.5x to our blended two-year forward EBITDA estimates for TELUS Technology Solutions and factoring in our one-year target for TELUS International; and (3) discounted FCF through 2030E factoring in a WACC of 8.5% and a terminal growth rate of 1.75%. We believe our target multiples are consistent with the company's growth and risk profile relative to Canadian peers, and a higher interest rate environment.

Risks to rating and price target

Risks to rating and price target include: (1) a prolonged and/or significant economic downturn; (2) a sustained increase in wireless competition and/or unexpected change in regulation resulting in higher churn and/or accelerated declines in postpaid ARPU; (3) inability to realize additional cost savings to improve wireline margins; (4) higher-than-forecast spectrum outlays; (5) emergence of irrational pricing in residential telephony, television, and/or Internet; and/or (6) higher interest rates and/or a reversal in fund flows out of the sector.

Exhibit 53 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 54 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Veeva Systems Inc. (NYSE: VEEV)

RBC Capital Markets, LLC
Rishi Jaluria (Analyst) (415) 633-8798, rishi.jaluria@rbccm.com

Rating: Outperform	Closing Price: USD 183.79
Price Target: USD 225.00	Implied All-in Return (%): 22.4

Investment summary

We like shares of Veeva for four primary reasons:

Veeva's domain expertise and deep customer relationships have created a market leadership position and a sustainable economic moat, in our view, limiting the threat of competition. As a result, Veeva has one of the highest average revenues per customer in software (~$1.6M last year).

We see multiple growth drivers for Veeva to maintain 20%+ subscription growth, including CDMS, Data Cloud, and Vault OLS (Outside of Life Sciences). We believe Veeva has a large TAM that will continue to grow with new products and that Vault, Veeva's content management platform, is a continued engine for innovation.

We believe Veeva's financial model is best-in-class, with a leading blend of growth and profitability. Veeva continues to show 20%+ organic subscription growth, while also seeing FCF margins approach 40% (which places Veeva in rare territory among SaaS companies), making Veeva a consistent "Rule of 40" company. This is the result of Veeva's product-led growth, fiscal discipline, and its unique GTM motion of the "Veeva Way", which involves slowly driving adoption through reference selling.

The life sciences market appears attractive, as it is a defensive industry that is also rather profitable (pharmaceutical companies have software-like gross margins of 70%+) and technology-forward (with the pandemic accelerating digital transformation initiatives). One key feature of life sciences is that the industry is more collaborative than others, which makes reference selling a key part of the GTM model. In addition, Veeva's blue chip customer base spans almost all of the top pharmaceutical companies, including household names such as Pfizer, Moderna, Johnson & Johnson, AstraZeneca, and Regeneron.

Valuation

Our $225 price target is based on 42x EV/CY23E FCF, a premium to the peer group, which we believe is warranted considering Veeva's leading blend of growth and margins, runway for future growth, and competitive positioning. Our price target supports our Outperform rating.

Risks to rating and price target

Risks to rating and price target include: (1) customer concentration, with the top 10 customers representing 36% of revenue; (2) international risk, with non-US revenue representing ~40% of total revenue; (3) CRM remains a significant part of the business at ~45% of total revenue (according to our estimates); (4) competition, including from vertical and horizontal software vendors; and (5) Veeva has a dual-class share structure; Class B shares hold ~52% voting power, which limits investors' ability to effect change at Veeva.

Exhibit 55 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 56 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

Ventas, Inc. (NYSE: VTR)

RBC Capital Markets, LLC
Michael Carroll, CFA (Analyst) (440) 715-2649, michael.carroll@rbccm.com

Rating: Outperform | **Closing Price: USD 43.35**
Price Target: USD 56.00 | **Implied All-in Return (%): 33.3**

Investment summary

Ventas, Inc. (VTR) is among the largest healthcare REITs and maintains a diverse portfolio consisting of nearly every healthcare property type. Seniors housing is the largest segment of the portfolio, generating ~48% of annualized adjusted NOI, and this space has started to recover from the impact of COVID-19.

Potential catalysts:

COVID spread subsides more quickly than anticipated. The largest risk to the healthcare REITs is the impact that the virus could have on results. If COVID-19 subsides and no new variants disrupt operations or the recovery is stronger than anticipated, results could benefit.

Access to multiple sources of capital could magnify investment trends. Management has been active sourcing several different types of capital including the launch of an open-end fund in 2020 and the GIC joint venture. Access to these different sources of capital could drive earnings growth higher if it allows management to be more aggressive in pursuing investments.

ESG focus could attract a new class of investors. VTR has been deemed a leader in ESG by multiple industry publications, and this focus could attract new investors.

Valuation

Price target justification: Our 12-month price target for shares of VTR is $56/share, which reflects a ~19.0x multiple based on our $2.94/share 2024 AFFO estimate. Our target multiple reflects a slight premium to the stock's pre-COVID average. We believe this is warranted given the superior SHOP growth outlook offset by the higher interest rate environment. Our target reflects a ~10% premium to our YE23E NAV of $50.93/share. Our price target supports an Outperform rating.

NAV estimate: We estimate the in-place NAV at $48.72/share assuming $40.05/share for current portfolio and $8.67/share incremental value with SHOP stabilizing at 87.5% occupancy.

Risks to rating and price target

The greatest risks to our estimates, recommendation, and price target center around general market conditions, consumer preferences and regulatory trends including, but not limited to, availability/cost of capital, seniors desire/willingness to move into a seniors housing facility, and changes to the healthcare delivery system including potential cuts to government funded programs. We highlight a few company-specific risks below, and investors can find a more inclusive risk section in the company's filings with the Securities and Exchange Commission.

Other company-specific risks include: **(1) new COVID variants could drive case counts higher again.** New variants could emerge that are more contagious and dangerous, driving a spike in COVID cases. We believe seniors housing is better protected than it was in 2020, but this could still impact the recovery; **(2) leverage is elevated and well above the long-term target.** Net debt to EBITDA (company-defined) is near 6.9x compared to the 5.0–6.0x target. We expect the SHOP recovery to drive these metrics lower over time; and **(3) triple net/loans could face cuts.** VTR has already worked through most of its NNN lease issues, but smaller problems could still dilute the near-term earnings trends.

Exhibit 57 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 58 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: link

WESCO International, Inc. (NYSE: WCC)

RBC Capital Markets, LLC
Deane Dray, CFA (Analyst) (212) 428-6465, deane.dray@rbccm.com

Rating: Outperform | **Closing Price: USD 154.54**

Price Target: USD 215.00 | **Implied All-in Return (%): 40.1**

Investment summary

WESCO is the leading North America-based electrical distributor in the +$100 billion highly fragmented North American electrical products distribution market with an estimated 7% market share, and 13% post-Anixter deal. We admire the scrappy, no-frills attitude that runs throughout the organization, as well as the strong historical free cash flow and debt pay-down history. After it emerged victorious from the Anixter bidding war, we estimate compelling upside based on pro-forma EPS and historically low multiples. We also like the fundamental scale benefits that come with the deal, including greater bargaining power with customers and suppliers that should help the company battle the ongoing tough price/cost backdrop.

Valuation

Our $215 price target assumes WCC trades to an undemanding 40% discount to our 18.0x SMID-cap 2024 target group P/E multiple, or 10.8x. This is at the low-end of WCC's historical (40%)-(10%) relative P/E range to discount the elevated leverage, integration risk following the Anixter deal, and risk that the macro meaningfully turns over. We balance this with powerful secular drivers of electrification, grid hardening, automation, data centers, and infrastructure spending. Our price target supports our Outperform rating.

Risks to rating and price target

Integration risk with Anixter.

Economic conditions. WESCO operates in cyclical industrial end markets and a slowdown in global activity could adversely impact sales and operating margins. Macro trends including inflation/deflation, commodity costs, credit availability, currency fluctuations, and supply chain could all materially impact results.

Competition and pricing. WESCO operates in the highly fragmented and competitive electrical products distribution market. With limited access to credit, smaller competitors may potentially cut prices and pressure WESCO's disciplined business model. There is also a growing risk from online distributors such as Amazon Business.

Acquisitions. WESCO has been active on the M&A front in this consolidating market and is exposed to overpaying for targets and integration headwinds. We remain confident in management's discipline on this front but acknowledge that large deals such as EECOL require considerable management attention and carry inherent integration risk.

Financial risks. Tightening credit standards and any disruption to credit markets could cause our estimates to be too optimistic.

Nonresidential end market. A slower-than-expected recovery in the nonresidential construction end-market could cause our estimates to be too optimistic.

COVID-19 impacts. WESCO's operations have exposure to the COVID-19 pandemic.

Exhibit 59 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 60 - Forward consensus P/E history



Source: Factset

Most recent company note: link

Required disclosures

Non-U.S. analyst disclosure

One or more research analysts involved in the preparation of this report (i) may not be registered/qualified as research analysts with the NYSE and/or FINRA and (ii) may not be associated persons of the RBC Capital Markets, LLC and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Conflicts disclosures

This product constitutes a compendium report (covers six or more subject companies). As such, RBC Capital Markets chooses to provide specific disclosures for the subject companies by reference. To access conflict of interest and other disclosures for the subject companies, clients should refer to https://www.rbccm.com/GLDisclosure/PublicWeb/DisclosureLookup.aspx?entityId=1. These disclosures are also available by sending a written request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7 or an email to rbcinsight@rbccm.com.

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors, including total revenues of the member companies of RBC Capital Markets and its affiliates, a portion of which are or have been generated by investment banking activities of the member companies of RBC Capital Markets and its affiliates.

With regard to the MAR investment recommendation requirements in relation to relevant securities, a member company of Royal Bank of Canada, together with its affiliates, may have a net long or short financial interest in excess of 0.5% of the total issued share capital of the entities mentioned in the investment recommendation. Information relating to this is available upon request from your RBC investment advisor or institutional salesperson.

Explanation of RBC Capital Markets Equity rating system

An analyst's "sector" is the universe of companies for which the analyst provides research coverage. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12 months relative to the analyst's sector average.

Ratings
Outperform (O): Expected to materially outperform sector average over 12 months.

Sector Perform (SP): Returns expected to be in line with sector average over 12 months.

Underperform (U): Returns expected to be materially below sector average over 12 months.

Restricted (R): RBC policy precludes certain types of communications, including an investment recommendation, when RBC is acting as an advisor in certain merger or other strategic transactions and in certain other circumstances.

Not Rated (NR): The rating, price targets and estimates have been removed due to applicable legal, regulatory or policy constraints which may include when RBC Capital Markets is acting in an advisory capacity involving the company.

As of March 31, 2020, RBC Capital Markets discontinued its Top Pick rating. Top Pick rated securities represented an analyst's best idea in the sector; expected to provide significant absolute returns over 12 months with a favorable risk-reward ratio. Top Pick rated securities have been reassigned to our Outperform rated securities category, which are securities expected to materially outperform sector average over 12 months.

Risk Rating: The **Speculative** risk rating reflects a security's lower level of financial or operating predictability, illiquid share trading volumes, high balance sheet leverage, or limited operating history that result in a higher expectation of financial and/or stock price volatility.

Distribution of ratings

For the purpose of ratings distributions, regulatory rules require member firms to assign ratings to one of three rating categories - Buy, Hold/Neutral, or Sell - regardless of a firm's own rating categories. Although RBC Capital Markets' ratings of Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis.

Distribution of ratings
RBC Capital Markets, Equity Research
As of 31-Mar-2023

			Investment Banking Serv./Past 12 Mos.	
Rating	Count	Percent	Count	Percent
BUY [Outperform]	824	56.05	236	28.64
HOLD [Sector Perform]	591	40.20	132	22.34
SELL [Underperform]	55	3.74	4	7.27

Conflicts policy

RBC Capital Markets Policy for Managing Conflicts of Interest in Relation to Investment Research is available from us on request. To access our current policy, clients should refer to https://www.rbccm.com/global/file-414164.pdf or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7. We reserve the right to amend or supplement this policy at any time.

Dissemination of research

RBC Capital Markets endeavors to make all reasonable efforts to provide research content simultaneously to all eligible clients, having regard to local time zones in overseas jurisdictions. RBC Capital Markets provides eligible clients with access to Research Reports on the Firm's proprietary INSIGHT website, via email and via third-party vendors. Please contact your investment advisor or institutional salesperson for more information regarding RBC Capital Markets' research.

For a list of all recommendations on the company that were disseminated during the prior 12-month period, please click on the following link:
https://rbcnew.bluematrix.com/sellside/MAR.action

The 12 month history of SPARCs can be viewed at https://www.rbcinsightresearch.com/.

Analyst certification

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.

Third-party disclaimers

Disclaimer

RBC Capital Markets is the business name used by certain branches and subsidiaries of the Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets, LLC, RBC Europe Limited, RBC Capital Markets (Europe) GmbH, Royal Bank of Canada, Hong Kong Branch, Royal Bank of Canada, Singapore Branch and Royal Bank of Canada, Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets'' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. RBC Capital Markets may be restricted from publishing research reports, from time to time, due to regulatory restrictions and/ or internal compliance policies. If this is the case, the latest published research reports available to clients may not reflect recent material changes in the applicable industry and/or applicable subject companies. RBC Capital Markets research reports are current only as of the date set forth on the research reports. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct, indirect or consequential loss arising from, or in connection with, any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior written consent of RBC Capital Markets in each instance.

Additional information is available on request.

To U.S. Residents: This publication has been approved by RBC Capital Markets, LLC (member FINRA, NYSE, SIPC), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets, LLC.

To Canadian Residents: This publication has been approved by RBC Dominion Securities Inc. (member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

To U.K. Residents: This publication has been approved by RBC Europe Limited ('RBCEL') which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ('FCA') and the Prudential Regulation Authority, in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. RBCEL accepts responsibility for this report and its dissemination in the United Kingdom.

To EEA Residents: This material is distributed in the EU by either RBCEL on an authorised cross-border basis, or by RBC Capital Markets (Europe) GmbH (RBC EG) which is authorised and regulated in Germany by the Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) (BaFin).

To Persons Receiving This Advice in Australia: This material has been distributed in Australia by Royal Bank of Canada, Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section 761G of the Corporations Act.

To Hong Kong Residents: This publication is distributed in Hong Kong by Royal Bank of Canada, Hong Kong Branch, which is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission (SFC) in Hong Kong, RBC Investment Services (Asia) Limited and RBC Global Asset Management (Asia) Limited, both entities are regulated by the SFC. This material is not for general distribution in Hong Kong to persons who are not professional investors (as defined in the Securities and Futures Ordinance of Hong Kong (Cap. 571) and any rules made thereunder.

To Singapore Residents: This publication is distributed in Singapore by the Royal Bank of Canada, Singapore Branch, a registered entity licensed by the Monetary Authority of Singapore. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is not indicative of future performance. If you have any questions related to this publication, please contact the Royal Bank of Canada, Singapore Branch. Royal Bank of Canada, Singapore Branch accepts responsibility for this report and its dissemination in Singapore.

To Japanese Residents: Unless otherwise exempted by Japanese law, this publication is distributed in Japan by or through RBC Capital Markets (Japan) Ltd. which is a Financial Instruments Firm registered with the Kanto Local Financial Bureau (Registered number 203) and a member of the Japan Securities Dealers Association (“JSDA”) and the Financial Futures Association of Japan (“FFAJ”).